52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
8 citations
,
July 2024 in “Journal of Advanced Research” In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.